Evidence map›Paper›PMID 36117665›Full record

ArticleChinese herbal medicines2022

Network pharmacology analysis to explore mechanism of Three Flower Tea against nonalcoholic fatty liver disease with experimental support using high-fat diet-induced rats.

Peixuan Wu, Shufei Liang, Yanping He, Rui Lv, Bendong Yang, Meng Wang, Chao Wang, Yong Li, Xinhua Song, Wenlong Sun

Open access · goldAbstract read
In one paragraph

Article in Chinese herbal medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Frontiers in pharmacology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Effect ofChinese herbal medicines · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Peixuan WuInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Shufei LiangInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Yanping HeInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Rui LvInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Bendong YangInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Meng WangInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Chao WangInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Yong LiShandong Tianyin Biotechnology Co., Ltd., Zibo 255000, China.
Xinhua SongInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Wenlong SunInstitute of Biomedical Research, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, China.
Shandong University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Nonalcoholic fatty liver disease (NAFLD) has become a common chronic liver disease that is harmful to human health. Moreover, there is currently no FDA-approved first-line drug for the treatment of nonalcoholic steatohepatitis (NASH) or NAFLD. Traditional Chinese medicine (TCM) is widely used to ameliorate liver diseases, such as the traditional ancient recipe called Three Flower Tea (TFT), which consists of double rose ( Methods: This study utilized bioinformatics and network pharmacology to establish the active and potential ingredient-target networks of TFT. Furthermore, a protein-protein interaction (PPI) network was constructed, and enrichment analysis was performed to determine the key targets of TFT against NAFLD. Furthermore, an animal experiment was conducted to evaluate the therapeutic effect and confirm the key targets of TFT against NAFLD. Results: A total of 576 NAFLD-related genes were searched in GeneCards, and under the screening criteria of oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18, a total of 19 active ingredients and 210 targets were identified in TFT. Network pharmacology analysis suggested that 55 matching targets in PPIs were closely associated with roles for NAFLD treatment. Through the evaluation of network topology parameters, four key central genes, Conclusion: In summary, our results indicate that TFT can prevent and treat NAFLD via multiple targets, including lipid accumulation, antioxidation, insulin sensitivity, and inflammation.

Indexed as

network pharmacologynonalcoholic fatty liver diseaseThree Flower Tea

Identifiers

PMID36117665
PMCPMC9476824
OpenAlexW4220693324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.